1. Home
  2. ALLE vs UTHR Comparison

ALLE vs UTHR Comparison

Compare ALLE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allegion plc

ALLE

Allegion plc

HOLD

Current Price

$159.24

Market Cap

13.9B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$488.92

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLE
UTHR
Founded
2013
1996
Country
Ireland
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
ALLE
UTHR
Price
$159.24
$488.92
Analyst Decision
Hold
Buy
Analyst Count
9
12
Target Price
$172.22
$495.08
AVG Volume (30 Days)
787.1K
424.3K
Earning Date
10-23-2025
10-29-2025
Dividend Yield
1.28%
N/A
EPS Growth
13.70
16.08
EPS
7.39
26.38
Revenue
$3,979,700,000.00
$3,128,400,000.00
Revenue This Year
$10.07
$13.64
Revenue Next Year
$6.53
$5.78
P/E Ratio
$21.53
$18.55
Revenue Growth
6.87
13.50
52 Week Low
$116.57
$266.98
52 Week High
$180.68
$492.62

Technical Indicators

Market Signals
Indicator
ALLE
UTHR
Relative Strength Index (RSI) 35.06 68.10
Support Level $163.27 $470.13
Resistance Level $167.01 $492.62
Average True Range (ATR) 3.10 10.72
MACD 0.01 -0.53
Stochastic Oscillator 2.11 89.55

Price Performance

Historical Comparison
ALLE
UTHR

About ALLE Allegion plc

Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: